Friday, the FDA lifted the clinical hold on Biomea Fusion, Inc.’s (NASDAQ:BMEA) ongoing Phase 1/2 clinical trials of the ...

Potential Biomea Fusion, Inc. ( NASDAQ:BMEA ) shareholders may wish to note that the Independent Director, Michael ...

I highlight potential of Biomea Fusion's diabetes drug amid competition, advises caution with stock due to risks. Read more ...

International diabetes pioneers and thought leaders from 11 countries will work with Biomea leadership to unlock the potential of menin science and beta cell biology to advance BMF-219 and Biomea’s ...

The U.S. Food and Drug Administration lifted a clinical hold on Biomea Fusion's ongoing studies of its experimental drug for ...

Fintel reports that on September 27, 2024, Truist Securities upgraded their outlook for Biomea Fusion (NasdaqGS:BMEA) from ...

REDWOOD CITY, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to ...

REDWOOD CITY, Calif. - Biomea Fusion Inc. (NASDAQ:BMEA), a biopharmaceutical company focused on the development of small molecule treatments for metabolic diseases and certain cancers, announced ...

REDWOOD CITY, CA – In a recent move signaling confidence in Biomea Fusion, Inc. (NASDAQ:BMEA), Director Michael J.M. Hitchcock has purchased 10,000 shares of the company's common stock.

Biomea Fusion, Inc. BMEA shares jumped 15.5% to $11.05. Biomea Fusion disclosed that the FDA lifted its clinical hold on ...

Joseph Pantginis, an analyst from H.C. Wainwright, maintained the Buy rating on Biomea Fusion (BMEA – Research Report). The associated ...